It would be interesting to do a retrospective analysis and comparison to the general population of the incidence of certain cancers, NASH, etc. in current patients who have been taking Leronlimab for specific time frames.

While the results would be anecdotal and not based on a controlled study, a finding that the Leronlimab treated patients had a significantly lower incidence of Cancers and/or Nash would be blockbuster news. That said, right now the data is available for less than a 1000 patients, but it would be an intriguing analysis.